





Ariennir gan Lywodraeth Cymru Funded by Welsh Government

2020 - 2021 Annual report

CONTENTS

Page 2	Introduction
Page 3	Foreword
Page 5	Lay Summary
Page 6	Our Workstreams
Page 10	Key Achievements
Page 24	Looking Forward

The Wales Cancer Research Centre is funded by Welsh Government through Health and Care Research Wales.

This report has been compiled with input from our public and patient involvement group.

INTRODUCTION

"Our vision is to work with cancer patients and other partners to develop and deliver research excellence that benefits the health and welfare of people in Wales and beyond."



The Wales Cancer Research Centre fulfill a broad range of roles is funded by the Welsh Government and is a key part of Health and Care academics, clinicians and Research Wales' infrastructure.

We perform and support cancer An External Advisory Board research of the highest quality, which builds on Wales' international research reputation, with a clear across the cancer research focus on collaboration, innovation spectrum and ensures that and improved patient outcomes.


Our vision is to work with cancer relevant. patients and other partners to develop and deliver research The centre has recently excellence that benefits the health received £5 million funding and welfare of people in Wales and renewal from the Welsh beyond.

We fund 27 full and part-time posts continue our research until and aim to improve collaboration in 2025. cancer research by bringing these staff and their colleagues together across Wales. Our researchers


including research nurses, biomedical scientists.

guides the centre in its work. It includes eight UK experts from our research is of the highest quality and internationally

Government, through Health and Care Research Wales, to



Above: locations of our staff across Wales



FOREWORD



Welcome to the Wales Cancer Research Centre's annual report for 2020-21 - the first year of our second quinquennium of funding from Welsh Government, via Health and Care Research Wales. Our sixth year has coincided almost exactly with the worst of the COVID-19 pandemic. It has been a difficult there was an initial, unavoidable year for so many in so many ways drop in overall activity, we are now and our hearts go out to all those affected by coronavirus, including cancer patients, their families and friends and, of course, our cancer research community in Wales.

Whilst coronavirus has had an inevitable impact on our work, I The following pages illustrate the Public and patient involvement and am immensely proud of the efforts undertaken by our dedicated teams of researchers throughout the crisis. Many of our staff were seconded to work on important patients at the centre of all that we cancer. alternative tasks such as developing do. Our new approach for the new vaccines and running clinical trials quinquennium, illustrated on page against COVID-19. Dozens from five, continues to keep patients at our cancer research community have commendably and selflessly

global challenge. One example of the families. unique contribution made by cancer researchers in Wales lies in the work

Our Personalised Prevention of Prof. Alan Parker's team, which you can read about on page 10.

Of course, our vital work against cancer has not stopped, thanks to the flexibility of our researchers to the extremely challenging circumstances. Despite the need to limit numbers of researchers on site, our laboratories have remained open throughout much of the lockdown periods, whilst many others have adapted to researching from home. Our multi-disciplinary research groups have continued to meet virtually, and events such as our conference for nursing and Allied Health Professional researchers have had to be online. Although back up and running at close to

Our full capacity. There have even been unexpected benefits, with savings in travel time and greater equity of access for researchers from across Wales.

impressive and inspiring efforts of our dedicated and determined research community who have been working hard together on keeping the centre of all that we do, focussing more than ever on the things that adapted their skill-sets to meet the matter most to patients and their Prof. John Chester, Director



- research focuses on developing and evaluating strategies to encourage healthier lifestyle choices, such as stopping smoking or maintaining a healthy diet.
- Our Enhanced Diagnosis work has a strong focus on interdisciplinary working to evaluate technologies that could improve the diagnosis of cancer.
- Our Improved Patient Outcomes workstream brings lab scientists and clinical researchers together to develop new, improved therapies for patients through our innovative Multi-Disciplinary Research Groups model.
- Optimised Patient Experience work ensures that the research that we conduct is driven by the needs and preferences of patients, their families and carers.

engagement remains the golden thread that ties our all work together, helping us to improve the lives of all those in Wales who are affected by

I Cleater

OUR RESEARCH IN NUMBERS



Grants won during reporting period

Grants won	Led by group	Group collaborating
Number	18	6
Value	£4.6m	£3.1m
Funding to Wales	£3.5m	£2.7m
Funding to group	£3.2m	£121,000
Additional jobs created for Wales	21	3
Additional jobs created for group	15	1





Number of publications



Number of public

involvement opportunities





LAY SUMMARY

The Wales Cancer Research Centre is conducting excellent research to improve treatments, clinical decision making and quality of life for patients. Cancer


At every stage of our work we aim to involve the public, is a disease no one wants to face, yet one in two of us carers and patients in our research. We believe that will develop it in our lifetime. In Wales alone, around they are not just the focus of our research, but should 120,000 people are currently living with cancer, and this be active participants, working with researchers to figure is set to almost double in the next fifteen years. plan, manage, carry out and publicise our work. We have appointed, trained and provide on-going support We are building on, and extending, ground-breaking to a team of six members of the public who work with research which has contributed to a doubling in cancer research staff across the centre. In the last year they survival in the last forty years. Now half of all cancer have ensured that the research we conduct is relevant, patients survive for ten years or more. We are working they have contributed to trial recruitment and improved hard to do even better. the process for informed consent for tissue donors.

We employ 27 members of staff at all levels of research, We regularly engage with the public to increase knowledge about the importance of cancer research, and how it is conducted in Wales. We organise events and bring our research to museums, festivals and busy public spaces. This allows the public direct access to our researchers through talks, activities and handson tours of our research sites. Our engagement work has impacted on young people's interest in studying science, public knowledge of personalised medicine and improved public awareness of clinical trials.

including nurses, doctors and laboratory researchers. Together they carry out research at every stage, from understanding the scientific basis of cancer to developing treatments that improve the health and wellbeing of individual cancer patients. Tackling cancer is a huge, global challenge, but we're successfully treating more cancers than ever before. We believe that, by working together, within Wales and internationally, we will meet the challenge.

If you are a member of the public who is interested We hope that the work of the Wales Cancer Research in getting involved in our research, please email us Centre, leading in several areas and collaborating on WCRC@Cardiff.ac.uk. effectively in others, will continue to play its part in helping us reach our goal.

Research that follows the patient journey



Public, Patients & Carers

OUR WORKSTREAMS

Personalised prevention

Our personalised prevention research focuses on developing and evaluating strategies to encourage healthier lifestyle choices in high-risk groups of people, such as stopping smoking or maintaining a healthy diet.

We are building on our strengths in screening, prevention and early diagnosis to reduce the burden of cancer on the people of Wales and beyond. We do this by conducting research that helps prevent cancer wherever possible, which picks up abnormalities at the pre-cancerous stage or which detects cancer in its earliest stages before it can grow and spread.

We are using population data to:

- Improve lung health by increasing awareness of lung cancer symptoms and encouraging people in deprived communities to seek help.
- Look at genetic and lifestyle factors and link these with data on bowel cancer awareness to investigate:
 - ♦ Utilising artificial intelligence to analyse data and better understand cancer risk.
 - Behavioural (e.g. diet) and therapeutic (e.g. \diamond prescribing medicines) prevention strategies in colorectal cancer.

Enhanced diagnosis workstream

We have a strong focus on inter-disciplinary working to evaluate technologies that could improve the diagnosis of cancer.

We are working on improving the detection of early cancers and pre-cancerous bowel polyps using new imaging technologies and specially engineered bacteria that help us to identify areas of risk.

We are developing more effective ways of predicting patients' outcomes using biomarkers - tests which tell us about the current state of a tumour or its likely behaviour. Two highlights in this area include:

• Telomeres are the end parts of a chromosome: • Treatments that combine drugs and radiotherapy measuring them gives an insight into a patient's prognosis. We are building on previous success in analysing telomere length and how this can be applied to help better predict how fast a patient's cancer will grow. Having this information will enable doctors to prescribe the most appropriate treatments.

 We are continuing to develop simple blood tests to spare patients a potentially intrusive biopsy by focusing on detecting DNA and exosomes that are released into the blood from tumours.

Improved patient outcomes

We are bringing lab scientists and clinical researchers together to develop new, improved therapies for patients through our innovative Multi-Disciplinary Research Groups model.

We are developing new cancer therapies to improve treatment options available to patients. We have particular strengths in molecularly-targeted 'biological therapies' which exploit the differences between cancer cells and normal cells such as:

- Small-molecule drugs which target abnormal cellsignalling processes within the cancer cell
- Immunotherapies which harness the power of the immune system to destroy cancer cells
- Engineered 'oncolytic' or 'cancer-busting' viruses.

We have already proven our ability to improve access for patients in Wales to the latest developments from laboratories in Wales and elsewhere via clinical trials in NHS Wales' hospitals. You can find out more about the success of our TaCTiCC trial and forthcoming trial of our innovative anti-Bcl3 drug on our website.

We are determined to increase the availability of clinical trials offering the latest experimental treatments to patients. These are particularly useful for those who have run out of 'standard' treatment options. We work closely with academic and commercial sponsors, trials units and clinical research facilities in Cardiff and Swansea to increase the quality, quantity and variety of trials available to patients. Conducting these types of trials helps us identify where treatments can be improved and guide where our laboratory work should focus. Our main strengths lie in:

- New ways of delivering drugs to cancer cells
- Studies of personalised treatments, including those using a patient's own immune system to tackle cancer
- New cellular therapies conducted in association

Treatment Centre (WM-ATTC).


We continue to develop a portfolio of new radiotherapy trials, with particular expertise in developing personalised studies for lung and upper GI cancers, and an emerging strength in brain cancers. We will design new research studies involving advanced radiotherapy techniques, including:

- Stereotactic radiotherapy, which uses 3D imaging to target high doses of radiation to the affected area with minimal impact on the surrounding healthy tissue.
- Novel combinations of drugs and radiotherapy for more effective combined treatment.
- Proton Beam Therapy, which uses the unique properties of protons to reduce the dose of radiation to critical structure, but is still a very new technology.

We extend our previous work on patient-reported In addition, we are working with experts in computer outcome measures (PROMs) and patient-reported science to employ automation throughout the experience measures (PREMs) to patients undergoing radiotherapy pathway and to study computerised chemotherapy for advanced lung cancer who have a analysis of imaging data (radiomics) of patients curative prognosis. undergoing radiotherapy. The systems we develop for this work will form part of the platform for large scale We are exploring difficult treatment decisions, assessing databasing of patients at different stages of their cancer patient experience before and during treatments, and journey. Our long term aim is to personalise treatment in the recovery phase. Patients who have opted not to choices for our patients using all available medical and undergo treatment will be an important comparator patient-related information. group.

Optimised patient experience

Patients are at the heart of everything we do. We We will work with UK partners to classify subjective work with our lay partners in 'co-production' which patient experience for use in clinical decision making. ensures that the research which we conduct is driven Our innovative 'decision support model' will be at the by the needs of patients, their families and carers, and heart of a new concept in Multi-Disciplinary Team of the community as a whole. This includes working meetings - 'SMART MDTs'. These SMART MDTs will cotogether to ensure that the best interests of patients produce personalised treatment plans based upon are always foremost in our research and to design data, including tumour characteristics, the patient's innovative studies which prioritise their personal values physiological resilience and individual values and and preferences at the centre of their personalised preferences.



with the Wales/Midlands Advanced Therapies treatment plan. This is particularly important in the setting of advanced disease, where eradicating the cancer may no longer be possible. In this case we want to find the best ways to balance a patient's quantity and quality of life to suit their individual wishes.


Personalised, physiological, pre-treatment assessment

Current methods for determining an individual patient's underlying fitness and predicting their tolerance of potentially toxic treatments are crude and prone to bias. We are assessing the relationship between a patient's tolerance of treatment and other aspects of their wellbeing, such as how it affects their ability to perform tasks, their metabolism, inflammatory response and physiological assessments.

Assessment of individual patient experiences, during and after treatment

Integration of patient experience into clinical decision-making

OUR STRUCTURE



KEY ACHIEVEMENTS

Cardiff scientists switch from cancer research to help develop coronavirus vaccine

at the start of the pandemic, they

virus.

researchers are highly adaptable and took up the challenge of combatting the pandemic

Our

Their work over the past seven years centred has on modified

adenoviruses such the common cold as

as viral vectors - or carriers - that can seek out and destroy cancer cells.

Over this time, Prof Parker and his Parker. team have a vast bank of different adenoviruses, and their work aimed

Prof Alan Parker's team usually to seek out - and recommission - the how we can usefully contribute.

switched their efforts They identified about half a dozen virus. to help in the fight viral vectors which could be useful against the new for encoding coronavirus antigens - the name for the part of the virus used to safely induce an immune response which may then offer protection against subsequent - but we're still doing what we're infection, or immunity.

> "Our aim was to produce potential to immunologists to test to see if they are able to induce an immune response that can protect against

work on reprogramming viruses so viruses with the potential to be used Everyone feels the same. Our role is they can target and kill cancer - but to deliver a vaccine for coronavirus. just a small part of the huge effort that is under way to help fight this

> "Our expertise is in tinkering with viral vectors for therapeutic benefit. We've changed tack slightly - from fighting cancer to infectious disease good at and drawing on what we know."

vaccines and then pass these on Many of our researchers were redeployed at the start of 2020 to tackle the pandemic. We are proud of the efforts they have all made coronavirus infection," said Prof to tackle the virus and to continue with vital cancer research under challenging circumstances.



Nearly half of people with potential cancer symptoms in first wave of pandemic did not contact GP, study finds

their GP, the initial findings of a UK- persistent symptoms. wide survey have suggested.

The research was carried out by Kate Brain, a health psychologist referrals, missed tests and later-Cardiff University and Cancer Research UK, with preliminary findings focusing on the experiences of 7,543 people from March to August 2020. The study was funded by the Economic and Social Research The policy briefing paper also to control the spread of COVID-19, Council. Our lay lead for public and patient involvement, Julie Hepburn, was a co-applicant on the study.

Possible cancer symptoms were commonly experienced during the first wave, the survey found, with 40.1% of participants (3,025 people) saying they had experienced at least one potential symptom.

Of those who experienced symptoms, a substantial proportion (44.8%) reported not contacting their GP for any symptom, even for red flags such as coughing up blood fuss (12%), difficulty with access unexplained lump or swelling (41% did not seek help) or a change in the not seek help).

Principal investigator Professor which may translate into delayed from Cardiff University's School of Medicine, said people had "put their health concerns on hold to protect "This suggests the government's the NHS".

outlines:

respondents reported feeling safe from COVID-19 if they needed to and investigations due to COVID: Worry about wasting healthcare safely." professionals' time (15.4%), worry seen as someone who makes a NHS services are open safely. (9.6%) were reported as barriers to seeking (4.8%).



A policy briefing paper on the



Nearly half of people who findings calls for coordinated Professor Brain said: "From the experienced possible cancer campaigns across the UK to early data we collected after the symptoms in the first wave of the highlight that NHS services are open first lockdown we can see that the COVID-19 pandemic did not contact safely for anyone with unusual or COVID-19 pandemic has affected public attitudes to seeking help for signs and symptoms of cancer stage diagnosis.

> message to 'stay home, protect the NHS, save lives' which was intended also sent a strong message to the public that cancer can wait. While More than two-thirds of we recognise that measures to control the spread of COVID-19 are essential, we also need to send attend an appointment at their GP a strong and clear message that (68.2%) or hospital (61.2%) – but cancer cannot wait, that people nearly three quarters (72.3%) were should contact their GP with any worried about delayed cancer tests unusual or persistent symptoms and that NHS services are open

> about putting extra strain on the Thereport recommends that further NHS (12.6%), not wanting to be work is needed to make it clear that

(30.7% of those who experienced to healthcare services (10.3%) and It concludes that clear information this symptom did not seek help), an worry about catching COVID-19 is needed to encourage confidence in contacting the GP promptly, seeking medical help. In contrast, explaining the changes to GP appearance of a mole (58.6% did remote consulting was not a practice procedures and what to common barrier to medical help- expect at a consultation, and to alleviate worries about NHS capacity and infection control.

> Clear information is needed to encourage confidence in contacting GPs promptly to report cancer symptoms



Research Inspires Me (RIME) Schools Engagement Project

We teamed up with Cardiff - 14). University to launch a competition Cancer Day.

Developed with researchers and poets, this new education pack aims to inspire a future generation of cancer

researchers skills mproving literacy

and

The

digital

RIME

competency.

Our education pack aims to inspire a future generation of cancer researchers

project (Research Inspires ME) features a quiz

tool to help children assess the cancer research facility. validity of medical research claims they find online and a competition Dr Kieran Foley, a consultant that challenges them to get creative and write a poem about cancer Hospital and a clinical researcher for research.

Bringing together the arts and who helped to develop the project. sciences, this free resource is designed for use by English, Welsh, He said: "There's sometimes a Research Centre and the Centre for PSE and science teachers who work tendency for people to picture a Trials Research, with funding from with key stage three pupils (age 11 scientist in a lab coat when they the Wellcome Trust.

and education pack to mark World The project invites school pupils to research involves using radiology write a poem about cancer research for a competition. To inspire them, teachers, poets lfor ap Glyn (National Poet of to improve the decisions about Wales) and Owen Sheers, pictured above, have composed works of their own, based on conversations with types of scans should be used and while some of the researchers tackling when. I really enjoy working with cancer in Wales. Their compositions have been transformed into two powerful film-poems that feature in the education pack. (See more on used in everyday practice. It's page 22.)

> The poets will pick one winner in Welsh and one winner in English who will receive £150 each in book that educates about tokens for their school and have field." cancer risk factors, a their poem displayed publicly at a

> > radiologist at the Royal Glamorgan Velindre Cancer Centre and Cardiff University, is one of the researchers

think of cancer researchers. My role is much closer to patients. My scans that patients have when they are diagnosed with cancer which treatments have the best chance of success and which a variety of people from different specialities and hospitals and seeing the research we do being wonderful to know that my work helps improve the lives of cancer patients and I hope this education pack will encourage young people to consider taking up a career in the

Over fifty schools have signed up to use the resources.

The films and education pack are available in Welsh and English and are free to download from our website. They have been produced in collaboration between Cardiff University, the Wales Cancer

What are the challenges to becoming a clinical research lead in cancer in the NHS in Wales?

Research is of key strategic East Wales). importance in the NHS in Wales. The NHS Wales cancer clinical community has much to offer and wider outcomes for cancer patients in Wales and beyond, through clinical research. Cancer Research UK is keen that Clinical Trial Units build a portfolio of trials. Leadership, including supporting and developing Chief Investigators, is required to engage in the development and delivery of cancer clinical research. We undertook a short survey to try to understand barriers to the development of such leaders in NHS Wales.

The survey was developed by Professor Richard Adams from the Centre for Trials Research and Jodie Bond from the Wales Cancer Research Centre, in collaboration with Dr Sue Channon and Dr Philip Pallmann from the Research Design and Conduct Service. (RDCS-South

The survey was completed by 80 practitioners, including oncologists, in improving the quality of care surgeons, nurses, physiotherapists, radiographers, psychologists and clinical scientists. The results of this survey show that there are barriers perceived and experienced at an individual and professional group level. While there is support available, through the RDCS and where needed through Clinical Trials Units in Wales, this needs better signposting, workloads need to be reviewed and time needs to be allocated within job plans for the development of this important work and to ensure succession planning for our future leaders. The survey has provided valuable information and areas for focus going forward and we are very grateful to all those who completed it. The survey results are available to download from our

Meet our new Public Involvement Academic Lead, Alisha Newman

website.

Partner for Public Involvement in undertake this important role. 2020.

My interest in the position stemmed organisation's wider infrastructure, from the desire to advance public we aim to take involvement to the involvement in research through next level through delivery of the application of my experience gained new five-year public involvement in past community education and action plan. This means inspiring development roles. This included wider understanding, greater buy in, eight years at CLIC Sargent, where and growth of public involvement, I worked with children and young to include a range of involvement people with cancer and their families to implement an award-winning UKwide service which supports their influence on decision-making, and is central to the charity's research, This work will be underpinned by

build on the strong foundation that purpose-built tool. These examples has been established through the will help researchers and the centre's research partner model, public to understand that through

I was appointed as the Wales and to harness the dedication and the achievement of our public Cancer Research Centre's Academic passion of the involved public who involvement ambitions, we will attain the ultimate reward of better research.

Together with support from the opportunities that support greater diversity in line with the UK Standards for Public Involvement.

development and influencing work. a pragmatic approach and tangible public involvement impact cases As Academic Partner, I am keen to which will be produced using our





Wales Cancer Bank wins biobank of the year

Biobanking Showcase event on 16th sponsor, Achiever Medical. October 2020.

treatments for cancer patients.

One of our closest collaborators, conversation. Dr Alison Parry-Jones, lockdown has given us challenges, the Wales Cancer Bank, was named the Operations Director for the as it has many other biobanks, but as the 2020 UK Biobank of the Year Wales Cancer Bank, accepted the we are now back up and running by the UKCRC Tissue Directory and award certificate from Gary Rooksby and supplying samples again to Coordination Centre at their annual who is a product specialist for award researchers. Hopefully the next 12

Dr Parry-Jones commented, "The The awarding panel were The Wales Cancer Bank collects Wales Cancer Bank is proud to samples of tissue and blood from receive this award and thanks the patients in Wales where cancer is sponsor, panel and the UKCRC a possible diagnosis. The samples TDCC. This is for the wonderful team performance across many of the are stored to form a biorepository we have - it has been a challenging criteria for the award. In particular to which researchers can apply for year, not only because of COVID their agility in responding to the biosamples and data. Thousands and lockdown but we were applying of their samples have been used for continuation of funding and we in research conducted across had a large internal (routine) audit the world in order to improve followed by an HTA inspection in lanuary. The staff were magnificent, pitching in to help with activities with the biobank's patient and This year's showcase event was held not in their job description - we public involvement activities. The virtually across five afternoons and managed to audit 7,000 consents panel commended the biobank for included some innovative breakout in three months in preparation for sessions to stimulate remote the audit and inspection. COVID and

months will be a little quieter!'

particularly impressed with the application from the Wales Cancer Bank as it demonstrated a strong COVID-19 pandemic, despite being primarily a cancer biobank. They felt that this showed a proactive quality which underpins their service. They were also impressed the overall quality of their resource.



Early Detection & Diagnosis Stakeholder Event



launched their Early Detection streams to researchers from across and Diagnosis (ED&D) Roadmap. Wales. This marked a timely opportunity Wales.

Cancer Research UK's ED&D important area.

Cancer Research UK recently Roadmap strategy and funding

to gather strategically important A presentation led by CRUK's ED&D partners to increase the mutual team was followed by introductions visibility of CRUK's ED&D strategy to some of our key partners and and relevant cancer research in areas of research strength. The concluding question and answer session proved invaluable in We held a virtual event on the 17th identifying areas of strategic fit to of March. The event introduced drive research forward in this vitally

Predicting success of hormone therapy in breast cancer patients

University NHS Trust and led by hormone therapy is often the best indicated activated RET can lead Velindre Cancer Centre and Cardiff treatment. There are many different to resistance to hormone therapy. University has found a potential ways in which breast cancer cells However, our data, which looked at new way of predicting the outcome become resistant to hormone cancer tissue samples from patients of breast cancer patients who are treatments, and one is thought to in the trial, clearly indicated that taking a drug called fulvestrant. be the activation of a 'signalling' patients with high RET levels in The findings were presented at the pathway in the cells involving a their cancers received much greater prestigious international European protein called RET. Studying the level benefits, which is likely to be as a Society of Medical Oncology of RET protein expression in patients result of fulvestrant treatment. I conference (ESMO), which was held on this trial led to this finding. The am delighted that we were invited online this year.

striving to improve the way analysed by the Centre for Trials at Cardiff University, have been treatments are delivered to Research at Cardiff University. All at the forefront of delivering new patients. Fulvestrant, developed patients took fulvestrant, and the clinical trials for cancer patients and by AstraZeneca, has been a trial assessed whether adding a this is a real recognition of the value successful drug in the treatment new drug called vandetanib could of the work we do here in Wales." of breast cancer, but this research improve outcomes further. The has identified a biomarker which research team found no evidence Mark added, "Only one in four appears to pick out patients who that patients receiving vandetanib cancer trials produce positive gain most benefit from the drug.

Discoveries like this mean that, on fulvestrant treatment whose for, I'm delighted that these findings potentially, doctors can more cancers have higher levels of the could go on to improve treatment accurately pick treatments that RET protein do much better. In fact, for patients." are more likely to work in an in this trial their cancer is controlled individual patient. This could not for over twice as long as those who As this finding was largely only save patients from undergoing have low RET levels and this is highly unexpected it will be important to unnecessary treatment, but it could statistically significant. also save the NHS money.

The trial, which was endorsed by phase trial research, and Mark choices for breast cancer patients. Cancer Research UK, looked at Beresford, of Bath University, copatients with advanced Oestrogen led on the study. Dr Jones said, "This Receptor positive breast cancer that finding was actually guite a surprise

Biosamples with trial data made available

A partnership between the Wales Cancer Bank and the Centre for Trials Research has presented a rare opportunity to access tissue and blood samples that come complete with associated trial data.

Samples from eight cancer trials are available. In January, we held an event for the research community, detailing more about how the data linked to these samples could benefit research projects.

Information about the samples and assocciated data can be found on our website.



A trial sponsored by Velindre has spread around the body, where as previous laboratory work has trial involved 165 patients from 19 to present these findings at ESMO. different hospitals across the UK Velindre Cancer Centre, together Cancer researchers are always and the data was coordinated and with the Centre for Trials Research

> gained additional benefit. However, results, and although ours didn't the trial has shown that patients show the results we were looking

> confirm this with further research, but it could lead to an additional Dr Rob Jones, who leads our early tool in making informed treatment

Industry update

Significant progress has been made the Welsh Government overseas Academy and the Wales Cancer and internationally.

& Vale UHB, Swansea Bay UHB potential funding avenues. Pilot variety of formats.

There have been early stage Another collaboration has been collaborations set up with pharma established with Salamanca companies such as Roche with University and Cardiff, Bangor and the Experimental Cancer Medicine Swansea Universities to explore Centre (ECMC) programme. There working and collaborating on The business innovation team are also a number of discussions European grant applications. going on with various other Further afield in China we have organisations and networks within had a request to set up a joint the UK and internationally. Through collaboration with XITU Suzhou progress throughout the project.

in engaging with industry in the UK offices, we have two companies wishing to engage with us; Canada in particular, within the areas of into the Chinese market. Through We currently have two Clinical artificial intelligence and data Research Organisations (CROs) that integration and very early stage are in negotiations with primary cancer detection. These discussions care and secondary care. A Letter of have already started with the Attend has been signed by Cardiff Quebec Regional government on and Betsi Cadwaladwr HB, in trying projects have been identified within to increase commercial trials in a the primary care setting to test the Al software.

Research Centre, exploring a list of patents ready for translational work the Welsh Government overseas and contacts within Cardiff University we are in negotiation with hospitals, pharma and biopharma companies within Henan Province, China.

We have been asked to sit on the advisory board for the new medipark being built next to the Grange Hospital, Newport. We will be feeding industry partners in to the site and will be advising on potential collaborations.

within WCRC is involved in the setup of spin-out companies from Cardiff University and will be steering the



Meet our new Director of Operations

It is with great pleasure that we within the area of cancer. introduce our new Director, of

a commercially-focused senior clinical operations manager with 20 years of experience in the private medical industry along with multiple management roles at a blue-chip retail company. His focus wll be to build our centre through improving our links with industry.

to meet members of the research community in person for guite national level but internationally. I just under Castle Coch for Synexus. some time, so we asked him a few questions to give you an top places in the UK to work within fanfare with executives flying in introduction..

working for the Wales Cancer in the home office? **Research Centre?**

I have spent over 14 years working within the health care sector a veg and herb garden that feeds and wanted a role that offered an opportunity to make a real difference to the health of the and enjoy reading non-fiction and people in Wales and beyond. history. While working as a manager of a clinical trials unit in Cardiff my What kind of challenges have you research into the industry led me faced in starting this new role to discover how far Wales was lagging behind not just the rest of the UK, but internationally in health management. This role within the Wales Cancer Research Centre is ideally placed to make a real impact biggest challenge.

Operations, John Jones. John is What are you enjoying most your career to date? about the role so far and what do you hope to achieve? the field of cancer.

Why were you attracted to How do you relax after a busy day

I have a wide variety of interests. I have a passion for cooking and have into my enjoyment of cooking and gardening. I practice yoga to stay fit

during lockdown? All my interactions have been virtual rather than face-to-face so engaging in personal interactions that help develop relationships has been the



What are you most proud of in

I am most proud of transforming a small 500 sq. ft. clinical trials What I am most enjoying about the unit with three tiny clinic rooms, role is discovering how much talent tucked away within an upper floor there is working within this field and of a business unit in a business park how many excellent opportunities into the one of the biggest private there are to make a real difference. trials units in the UK. I moved and My goal is to make the centre a developed the tiny unit into a two self-sustaining organisation that storey 10,000 sq.ft. state of the art, It is unlikely that John will be able can bring together the talent within modern purpose built unit with eight Wales and work not only on a large clinic rooms and laboratory want to help make Wales one of the It was successfully opened to great from all over the world and TV and radio coverage



Scientists develop rapid test for diagnosis of rare set of genetic conditions

and Queen Mary University of researchers say it can be applied of rare and debilitating genetic frozen blood samples. conditions.

information.

symptoms, including bone marrow failure, pulmonary fibrosis, cancer and liver disease in adults and children. There are currently about 1,000 people living with telomeropathies in the UK, many of which are undetected.

Now, our researchers have

developed a rapid laboratory test for diagnosing showing **Telomeropathies** the many can result in a different types of range of symptoms, symptoms including cancer. that can arise from

throughput single telomere length

analysis (HT-STELA), is a DNA-

based blood test that provides

telomeropathies.

London have developed a rapid test to a broader range of samples than many parts of the body, including for the diagnosis of a constellation existing tests, including fresh or

The research was led by Professor Telomeropathies are caused by Duncan Baird at Cardiff University premature shortening of the tips of and Professor Tom Vulliamy at chromosomes, the DNA molecules Queen Mary University of London which contain our genetic and is published in the journal Human Genetics.

They can result in a range of Professor Baird, one of our Associate Directors, said: "If a patient presents with a severe symptom such as bone marrow failure we can now test, more accurately and rapidly than ever before, if this is the result of a telomeropathy, thereby speeding up the process of providing a diagnosis for these patients.

> "We believe the speed and accuracy of this technology will provide a step-change in the clinical utility of patients telomere testing."

> > Telomeres are structures that shortening has been shown to have protect the ends of chromosomes such a significant impact on life and they shorten with advancing age. When they become too short, cells are no longer able to divide, and scientists believe this may underlie the natural ageing process in humans.

In telomeropathies, they shorten The technique, called high- too early because of defects in their maintenance caused by mutations in specific genes.

Researchers at Cardiff University high-resolution information. The Dyskeratosis Congenita (DC) is a telomeropathy that affects abnormalities in the skin, fingernails and toenails and mouth, in both adults and children.

> To test the efficacy of the new tool, the researchers used it to compare telomere length in 171 healthy individuals with 172 patients who had diagnoses for DC and other related disorders.

They found the group with these diagnoses, particularly the younger patients, displayed shorter telomere length.

HT-STELA also allowed the researchers to identify a smaller group of patients where telomeres, shorter than that expected by age, caused a five-fold greater risk of death.

"We believe this is the first time that the extent of telomere expectancy," said Professor Baird.

The test is provided by the Cardiff University spin-out company TeloNostiX that has set up the technology in a clinical testing laboratory. The work was funded by the Medical Research Council, the Wales Cancer Research Centre. Cancer Research UK and the Welsh Clinical Academic Training (WCAT) programme.



Placing patients at the centre of the decision making process in advanced lung cancer

Treatment outcomes should be measured on the basis of what the patient has defined as important rather than on tumour size alone.

In the Marie Curie Palliative Care were interviewed to explore their profiles, the risk is that in the Research Group's PACT study, experiences of the decision making context of advanced lung cancer researchers followed the journey process and how helpful they found the patient's own voice and needs of patients with advanced lung the consultation. Perspectives were are overlooked which might result cancer as they navigated through also sought from family members, in avoidable harm." the process of deciding whether healthcare professionals and expert non curative chemotherapy would stakeholders, comprising a total of Professor Nelson added "Early benefit them or not. Despite the 99 interviews. best intentions, chemotherapy may have serious complications in those The study found that initial or as an alternative to palliative with advanced disease, increasing treatment recommendations didn't chemotherapy, and the outcome the risk of early death, unpleasant always take account of patient's of any treatment measured on the side effects and worsening quality personal life priorities and social basis of what the patient has defined of life. Careful planning and circumstances in the context of a as important rather than on tumour discussion is needed in order to terminal illness, and the impact size alone. In this way the benefits make an individualised approach to that chemotherapy might have. of any treatment will better reflect treatment.

leads our personalised experience plans within set timeline targets. care." research explained "I was struck Both doctors and patients often months."

decisions were made within a Oncologist and member of the the Stepping Stones Lung Cancer multidisciplinary team of lung research team said "At a time Research Fund at Velindre Cancer cancer specialists and how these when cancer treatment decisions Centre. The publication can be found decisions were subsequently are increasingly based on tumour here: Chemotherapy decisiondiscussed with patients. Patients genetics and immunological making in advanced lung cancer: a

palliative care.



palliative and supportive care should be more openly explored alongside, The focus of discussions was often the impact on lived experience and on the cancer and not the person, quality of life, helping lung cancer The study's Chief Investigator, something which appeared driven patients and their families make Professor Annmarie Nelson, who by a pressure to initiate treatment more informed choices about their

by the statistic that 10% of patients struggled with discussions around The PACT study raises several with advanced lung cancer die the life-limiting nature of their opportunities to improve how lung within 30 days of commencing condition where prognosis was cancer teams can place patients at or whilst on chemotherapy. It often measured in months. This the centre of the decision making seemed important to me that prevented open conversations process. The Research Centre we take a careful look at how we about alternatives to chemotherapy is already developing a tool for decide whether chemotherapy is such as focusing on supporting supporting teams in this, as well as in a person's best interests or not wellbeing, participation in family reviewing the current methods used when their prognosis is limited to life and early access to high quality for evaluating a patient's fitness for chemotherapy.

The researchers observed how Dr Jason Lester, Lung Cancer The PACT study was funded by prospective qualitative study.

Spotlight on: our public & patient involvement group

Our public and patient involvement group are central to everything we do. They work with our researchers to ensure that the work we do is relevant and valuable. We would not be the organisation we are without them.



Velindre Futures

Velindre Cancer Centre.

of past years, I was fortunate to get a substantial involvement opportunity at Velindre Hospital. That Health Trust have a pivotal 10 year strategy called 'Velindre Futures' which involves a new core hospital and service redesign. As part of this significant change, cancer related research is also being prioritised. In brief, there is recognition that research active environments have better patient outcomes and tend to retain staff who are leaders in their field of study and specialist treatment.

I was one of two public workforce is key. representatives on the research task and finish group. The other Thus it was important that current was a male who had been part barriers were openly identified and of clinical trials whilst receiving costed solutions outlined in any treatment at the hospital. Thus strategy. I helped to keep focus public involvement.

tells us about his work with was Professor Mererid Evans, a noted clinician and researcher. Other group members were drawn As a Wales Cancer Research Centre from current research pockets Research Partner in this strangest across Velindre and from partner bodies such as Cardiff University. Importantly, the Velindre Board were also represented. Both of us public members were very well supported and listened to on the you put it on the table that simply group.

> So what did I 'bring to the (working) party?' I have a lot of experience of this case I could tell that the clinical researchers were very engaged. It was clear that most group members felt carving out properly funded

he spoke passionately of his first on the achievement pathways. A

Research partner Bob McAlister hand experiences. The group chair number of times I sent additional thoughts to the Chair in between meetings and had extra catch ups. This is some of the feedback that I received from a group member: I have to say that your contributions at the Velindre Futures meetings are very important. You manage to get the group to focus attention on the "path to getting things done" and having a strategy isn't enough. It's the classic case of people listening to the objective bystander.

> such groups and their dynamics. In I did not write the very impressive eventual strategy, I could not speak with the passion and experience of the other public member, but I know that some of my input and protected research time and was important and well received. building critical mass across the Also both of us wrote supportive narratives which were recorded and used to start every Velindre webinar when the completed strategy was introduced to the staff. Overall, this was a very rewarding example of

A year in the life of our public and patient involvement group

Julie Hepburn, our lay lead for this year are: patient and public involvement, shares her thoughts on the past

Aligning research partners to year.

The new funding year started in April 2020 with several challenges for our public involvement advisory group to overcome before we could focus on our plans for the future. COVID 19 was the most significant challenge, • necessitating new ways of working and requiring us all to become more proficient at distanced working and the associated use of online platforms. Vacancies existed at the start of the year for both the group project officer and the academic partner, which temporarily delayed progress. Fortunately, these roles were filled quite quickly, which enabled us move forward with our plans. Alisha Newman, our new academic partner, has written an introductory article on page 13.

Requests from the research community for our help and advice slowed at the start of the year as many researchers were reallocated to clinical work because of the pandemic. We took this opportunity to push forward with some of the pre-existing plans outlined last April, and to re-examine the research partner role and our aims for the future.

Areas we have made progress on

- pages 8 9).
- in the area.
- advanced.



work with the new structure. All areas of the WCRC organogram now have a linked research partner to work with and discuss ideas and requests (see

Appointment of a research partner in north Wales. Mark Edwards was appointed in September. His presence has been welcomed by researchers

Public involvement in research action plan: a new five year action plan has been produced and working groups are being established to deliver it. Some key actions on impact, diversity and inclusion have already been

Diversity and inclusion. Key actions within the public involvement action plan aim to find ways of capturing opinions/ suggestions from beyond our group. This includes working with the Cardiff University to attract a broad cross section of society to whom we can promote the growing number

of research and teaching involvement opportunities.

- Rapid Response Group. A new group of 10 members of the public with experience of cancer was appointed in March 2021. Currently being piloted with support from Health and Care Research Wales, the group's function is to respond quickly to researchers wanting public involvement help with funding bids when deadlines are imminent.
- Development of a tool for recording and reporting public contributors' impact on research against the UK standards for public involvement. The tool is being finalised and will be piloted in five research projects before final release to the wider research community later this year. Progress in the area of impact capture and reporting would be groundbreaking and of significance beyond the centre.

immediate research partner Our new action plan outlines future areas for development and, with the support of the research community School of Medicine engagement in delivering it, the next four years and involvement group to pilot should prove to be an exciting use of an online social network and productive time for our public involvement work.

The Song of Us

Composed by author, playwright and poet Owen Sheers, based on conversations with our researchers (see more on page 12).

And so what makes us breaks us a scratch in the genetic record, the cell's needle catching on its error to knit an echoed note of darkness link by link, into the fabric of the body's living brightness.

The twitching tick of a molecular clock, stuck. A fledgling, nesting its repeating song in the tissue of a lung, a breast, under the skin. An embryo of ending, inherited or acquired, and growing now too, on a diet of its own broken chant of Begin, begin, begin.

Which is where we come in. Because what breaks us, makes us the lookers, the thinkers, the intimate readers of the body's script written under the skin. The travellers down paths of trial and error, often alone - in a lab, a room, in bed at home -

and yet always together bonded as we are by the ideas that we grow, that flow between us through capillaries of thought across borders, ages, religions, coursing with the songs of our inspirations, the ideas which in their movement, multiply.

Millions of small steps becoming strides, leaps, the stories and records of what we've seen, noted and known. A global organ of knowledge, inherited or acquired; an arsenal of thought and hope combined that when applied can unravel that knitted shadow

and make time grow again. Because knowing that what makes us, makes us, this is also what we do under the microscope's bright eye, through the long hours of silent thinking, in the deciphering of code and gene,

in the enquiries at the needle's curious point -Make time, and once more set it free through the lives of people like you and me. Time for love to breathe, to see. For a mother to watch her children play or for children to know their father

tomorrow as well as today. To take the lives unlived that we might glimpse in the image on a screen, and make that image sing a different tune, a new thought-created song that knits hope from failure,

and that puts it on the record that by working together we can begin, begin, begin to imagine a different future and make that future happen.

Putting patient need at the heart of brain cancer trials

Researchers at Cardiff University either never report it, or do not quality of life, helping brain cancer have been awarded £155,000 from the Brain Tumour Charity to develop a standardised way of recording patient-reported outcomes for brain tumour trials.

Brain cancer studies traditionally focus on tumour size and maintaining patient survival. But there is growing recognition that studies need to better consider information about outcomes such as quality of life. This is particularly relevant in brain cancers like highgrade glioma, where survival benefits are modest.

Quality of life naturally means something different to every patient. Some patients might want to prioritise quantity of life over quality – perhaps they have a grandchild on the way or want to make it to a family wedding. Others Prof Anthony Byrne, Chief Centre and the Centre for Patient may prefer to prioritise their fitness over survival length to enable them to lead a more active life.

Many brain tumour trials gather information about patients' quality of life, but the vast majority

assess its importance alongside patients and their families make tumour response. There is also no informed choices about their care. standardised way of measuring best ways of assessing patients Tessa Jowell BRAIN MATRIX trial) Anthony Byrne and his team at support clinicians with decision CardiffUniversitywillseekconsensus making based on a patient's unique amongst patients, families and researchers about essential areas our patient data can be evaluated be collected across every glioma of patients with different types of trial. The consensus will produce a brain cancer." patient-oriented Core Outcome Set studies. COS development in other the results are hoped to improve and consistency of information in the NHS and beyond. captured, which enables better data sharing to improve the way we The project is a collaboration routinely treat patients.

glioma studies. It will ensure that and Birmingham Trials Unit. future trial results reflect impacts of treatment on lived experience and

Nurse & allied health professional meeting

The third annual nurse and AHP conference was hosted online this year. It benefited from a geographically diverse attendance which has previously proved to be an issue for in-person events.

Prof. Mary Wells (Lead Nurse for Research at Imperial College Healthcare NHS Trust and a Professor of Practice in Cancer Nursing at Imperial College) joined as our keynote speaker for the conference.

Other sessions included updates from regional representatives, the Research Design Service and a group discussion around building research capacity.





quality of life, which makes "The project has also established comparing studies to find the strong links with another trial (the very difficult. To remedy this, Prof that is specifically designed to situation. Working together means of patient/family experience to in the context of a broad spectrum

(COS) to be applied across all UK The study will run for 20 months and conditions has improved the quality the way glioma patients are treated

between the Marie Curie Research Centre, the Wales Cancer Research Investigator for this study, said, "This reported Outcomes at Birmingham project will produce a high quality, University as well as cross consistent approach to measuring collaboration between Cardiff patient and family outcomes in University Centre for Trials Research

LOOKING FORWARD

first six years.

emphasis on prevention and early global effort against cancer. diagnosis, patient outcomes and experience. The realisation of our In the post-COVID, post-Brexit from across Wales. The centre's ambitions in each of these important research funding environment, it areas will improve our profile, in will be more important than ever the UK and internationally, thereby to ensure sustainability of cancer encouraging further investment research in Wales – in both financial and new collaborations. This will and human resource areas . It will also help us to provide top-class be vital – literally – to secure longresearch training and to attract top term funding from a variety of researchers from outside Wales, public, commercial and charity generating a diverse, outward- funders. In addition, we must looking and forward-thinking develop and attract the very best future, based upon collaborative leadership team.

research strategy. Many members Wales. of the cancer research community, contributed to the evolution of

With the worst of the coronavirus Although inevitably delayed by the Director. It's therefore important pandemic hopefully now behind us, pandemic, I am encouraged that that I take this opportunity to thank the Wales Cancer Research Centre Health and Care Research Wales will be working harder than ever to have committed to ensuring its build on the many successes of our imminent completion. It will be a and a pleasure to be the founding blue-print for success and a clear Director of WCRC. I'm proud to have illustration - within our community been a part of an immense WCRC An immediate goal will be to fully and to our funding partners - of a team effort, and I feel privileged to embed our increased strategic unique Welsh contribution to the have worked with so many talented

within the centre and beyond, have Writing this forward look has been poignant for me, as it will be my this important, unifying document. last before handing on the role of

the many colleagues and friends who have made it both a privilege cancer researchers and dedicated patient and public representatives, success to date is due to the hard work and determination of a large team which is much greater than the sum of its parts. I will be forever grateful to everyone who has been involved, in so many different ways.

I fervently believe that we have built a strong platform for the of the next generation of leaders leadership and an inclusive team in cancer research to drive our spirit, and that this will serve us well A key factor in our on-going success research forwards and ensure a in achieving our ultimate ambition will be the new all-Wales cancer vibrant future research culture in of reducing the burden of cancer for patients, their families and carers, and our community, in Wales and beyond.

- Prof John Chester, Director





www.walescancerresearchcentre.com 02921 848970





